MAML2 and bladder transitional cell carcinoma: From these, a prognostic risk model for BLCA patients was developed based on the expression levels of the 14 CSRGs: risk score = (-0.289 × SH2D2A exp) + (-0.185 × LARGE1 exp) + (-0.205 × FAM13A exp) + (0.795 × SCAMP2 exp) + (-0.390 × NLRC5 exp) + (-0.082 × FXYD4 exp) + (-0.235 × FARP1 exp) + (-0.127 × C4orf19 exp) + (0.150 × C1QTNF7 exp) + (0.151 × IGDCC3 exp) + (-0.087 × B3GALT5 exp) + (0.293 × MAML2 exp) + (0.049 × KRT6B exp) + (-0.201 × ZNF350 exp) (Figure 1D).